Navigation Links
Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
Date:6/18/2009

uring the 4 week treatment period, for patients receiving CollaRx GENTAMICIN TOPICAL compared to 80% in the control group receiving standard therapy alone. Comprehensive results from this trial are expected in July 2009.

Another study is investigating the product for the treatment of mildly infected diabetic ulcers. The safety and efficacy of low dose CollaRx GENTAMICIN TOPICAL (one 5cm x 5cm sponge containing 32.5mg gentamicin administered daily) is compared to once daily 750mg oral levofloxacin (the current standard of care at its recommended maximum daily dose) in a prospective, randomized design. The study is fully enrolled and provisional findings indicate that mono-antibiotic therapy with CollaRx GENTAMICIN TOPICAL results in a similar number of clinical cures/improvements as the comparator establishing that the product could indeed be most effective as a stand alone treatment. Furthermore, the preliminary pharmacokinetic data have consistently demonstrated extremely low systemic concentrations of gentamicin in line with expectations for the delivery system. Final clinical, microbiological and pharmacokinetic results of this trial are expected in August 2009.

The third phase 2 trial is evaluating the product for the prevention of diabetic ulcer infection versus placebo control (collagen sponge) in a randomized, double-blind design. In this study, one 5cm x 5cm sponge (containing 32.5mg gentamicin in the treatment group) was administered twice weekly for the first 4 weeks and once weekly for a further 8 weeks. Provisional findings indicate a much reduced infection rate of 6% in the treatment group versus 36% for the placebo control. Completion of a more detailed statistical analysis is expected by July 2009.

Dr. Michael Myers, Innocoll's President and CEO commented, "These provisional findings from our US phase 2 program of three controlled clinical trials are most encouraging. We are particularly pleased to
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge
2. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
3. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
4. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Innocoll Announces Closing of $30 Million Equity Financing Investment
6. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
7. Quest Diagnostics Announces Final Tender Offer Results
8. Precision Stability Storage Announces Upcoming Expansion
9. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
10. Wyeth Announces Holder Right to Surrender Convertible Debentures
11. Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... , July 11, 2014 ... to announce the appointment of John P. Donoghue ... Biotech   in  Geneva . The ... Campus Biotech in Geneva , has ... recognised neuroscientists. John P. Donoghue , founder of ...
(Date:7/11/2014)... 11, 2014 Cayenne Medical, Inc., ... in the soft tissue reconstruction segment, announced the ... for surgeries involving the shoulder and extremities. The ... novel, inserter-controlled deployment method. The unique delivery eliminates ... anchor pull-out, or anchor displacement (also commonly know ...
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6
... Medicago Inc. (TSX: MDG), a biotechnology company focused ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... applications under the Patent Cooperation Treaty (PCT) that ... proteins and VLPs. "The extraction and ...
... strings, connecting bones to muscles that raise an eyebrow or ... an unusually forceful or awkward pull on the strings leaves ... to repair over 300,000 of these injuries every year, and ... Using a combination of nanoscience and biomedical and civil ...
... and Opportunity Advisors LLC, a subsidiary of Ramius LLC (collectively, ... CYPB ) has denied Ramius, legitimate request for a list ... shares and has launched a tender offer to purchase all ... per share in cash.  Ramius requested the stockholder list materials ...
Cached Biology Technology:Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications 2Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications 3The Achilles' heel of tendons 2The Achilles' heel of tendons 3Cypress Denies Ramius' Legal Right to Stockholder List Materials 2Cypress Denies Ramius' Legal Right to Stockholder List Materials 3
(Date:7/11/2014)... Stem Cell scientists have set a "mouse TRAP" to ... by a recent study published in the Journal ... uses a technique called TRAP to extract cellular and ... Invented by scientists at the Rockefeller Institute for Medical ... to the protein-making machinery, or ribosomes, of the cell ...
(Date:7/11/2014)... of researchers, including scientists from the Max Planck Institute ... a major step in understanding photosynthesis, the process by ... oxygen in its atmosphere and which is therefore crucial ... , The researchers report the first direct visualization of ... step in which a specific protein complex, photosystem II, ...
(Date:7/11/2014)... division of the striatum is also involved in ... of substance P in the striatal marginal division ... his team, College of Biophotonics, South China Normal ... P receptor, neurokinin 1 was highly expressed in ... rats. Unilateral or bilateral injection of an antisense ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... Researchers at Oregon State University have discovered that the circadian ... far more susceptible to pesticides at some times of the ... said, it may be possible to tap into this genetic ... vulnerable to a specific pesticide, and use that information to ...
... Park Ridge, Ill. (August 12, 2009) Research published ... levels of total blood choline are associated with a 2.5-fold ... are birth defects of the brain and spinal cord, and ... According to the Centers for Disease Control (CDC), an estimated ...
... to carry diseases lethal to many unique species of ... via aircraft, according to new research published today. ... previously thought to have been introduced to the Galapagos ... scientists from the University of Leeds, the Zoological Society ...
Cached Biology News:Biological clocks of insects could lead to more effective pest control 2Biological clocks of insects could lead to more effective pest control 3Essential nutrient found in eggs may help lower risk of neural tube defects 2Essential nutrient found in eggs may help lower risk of neural tube defects 3The tourist trap 2
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Applications: Immunohistochemistry, ISH, FISH, CISH....
... fit into the Universal Test ... to greatly increase your microplate ... plates at an angle, and ... shaker at once for quick ...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
Biology Products: